Informazioni sul prodotto
LDN-57444 is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and inhibits its activation. LDN-57444 is being developed for the treatment of squamous cell carcinoma, which is a type of skin cancer. The drug has been shown to inhibit tumor growth in animal models by inhibiting body formation, promoting autophagy, and reducing mitochondrial membrane potential. LDN-57444 has also been shown to inhibit the proliferation of human cancer cells in vitro and decrease cardiac arrhythmias. LDN-57444 binds to EGFR with a hydroxyl group on its structure that interacts with the EGFR's active site. This binding prevents EGFR from activating downstream signaling pathways, such as those involving phosphatidylinositol 3-kinase (PI3K) and Akt kinase, which are involved in cell proliferation and survival.
Proprietà chimiche
Richiesta tecnica su: LDN-57444
Si prega di utilizzare piuttosto il carrello per richiedere un preventivo o un ordine